Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) saw unusually large options trading activity on Wednesday. Traders purchased 40,671 call options on the company. This represents an increase of approximately 57% compared to the average daily volume of 25,968 call options.
Insider Activity at Tempus AI
In related news, CFO James William Rogers sold 11,529 shares of Tempus AI stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $55.00, for a total transaction of $634,095.00. Following the completion of the sale, the chief financial officer owned 114,866 shares of the company's stock, valued at approximately $6,317,630. The trade was a 9.12% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Eric P. Lefkofsky sold 250,000 shares of the company's stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $42.06, for a total transaction of $10,515,000.00. Following the completion of the transaction, the chief executive officer owned 200,000 shares in the company, valued at approximately $8,412,000. This trade represents a 55.56% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 684,424 shares of company stock worth $33,255,565. 24.26% of the stock is owned by corporate insiders.
Institutional Trading of Tempus AI
Several large investors have recently made changes to their positions in the company. GC Wealth Management RIA LLC bought a new stake in shares of Tempus AI during the 4th quarter worth $399,267,000. Voloridge Investment Management LLC grew its position in Tempus AI by 183.0% in the third quarter. Voloridge Investment Management LLC now owns 1,607,083 shares of the company's stock valued at $129,708,000 after acquiring an additional 1,039,176 shares during the last quarter. AQR Capital Management LLC bought a new position in Tempus AI in the second quarter valued at about $54,020,000. Amova Asset Management Americas Inc. raised its stake in Tempus AI by 23.4% during the first quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company's stock worth $195,549,000 after acquiring an additional 821,490 shares in the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. raised its stake in Tempus AI by 23.4% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company's stock worth $195,636,000 after acquiring an additional 821,490 shares in the last quarter. Institutional investors and hedge funds own 24.22% of the company's stock.
Tempus AI Price Performance
Shares of TEM traded up $9.90 during trading hours on Wednesday, hitting $59.26. 9,242,012 shares of the company were exchanged, compared to its average volume of 5,764,655. The company has a market cap of $10.69 billion, a price-to-earnings ratio of -40.78 and a beta of 3.58. Tempus AI has a fifty-two week low of $40.77 and a fifty-two week high of $104.32. The company has a quick ratio of 3.16, a current ratio of 3.30 and a debt-to-equity ratio of 3.06. The firm's fifty day moving average is $51.86 and its 200 day moving average is $51.18.
Tempus AI (NASDAQ:TEM - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The company reported ($0.04) EPS for the quarter, beating analysts' consensus estimates of ($0.14) by $0.10. The business had revenue of $382.49 million during the quarter, compared to the consensus estimate of $379.69 million. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.Tempus AI's revenue for the quarter was up 21.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.22) earnings per share. On average, equities analysts anticipate that Tempus AI will post -1.38 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of research firms have recently weighed in on TEM. Weiss Ratings raised Tempus AI from a "sell (e+)" rating to a "sell (d-)" rating in a report on Wednesday, August 12th. Guggenheim upped their price target on shares of Tempus AI from $60.00 to $65.00 and gave the company a "buy" rating in a research note on Thursday, July 16th. Lake Street Capital lowered shares of Tempus AI to a "hold" rating in a research report on Monday, July 20th. Piper Sandler lowered their price target on shares of Tempus AI from $58.00 to $56.00 and set a "neutral" rating on the stock in a research report on Tuesday, August 4th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $75.00 price objective on shares of Tempus AI in a research note on Friday, July 31st. Nine equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $64.92.
Read Our Latest Analysis on TEM
About Tempus AI
(
Get Free Report)
Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.
The company's core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Tempus AI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tempus AI wasn't on the list.
While Tempus AI currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
